Psoriatic arthritis treatment market

Q: Which is the prominent region in the market?

North America is the prominent region in the market. Read more

Psoriatic Arthritis Treatment Market, by Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease-modifying Antirheumatic Drugs (DMARDs), Biologics, and Others), by Product Type (Prescription and Over The Counter), by Route of Administration (Topical, Oral, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Request Free Sample

Nov 2021
CMI4624
260 Pages
Excel & Pdf
Pharmaceutical

Summary

Psoriatic arthritis can cause pain, swelling, and stiffness in and around your joints. It affects people who already have the skin condition psoriasis. This causes patches of red, raised skin, with white and silvery flakes. Psoriatic arthritis can cause a number of symptoms such as joint pain, swelling around the body. The main symptoms is pain, swelling, and stiffness because of inflammation inside a joint. This is known as inflammatory arthritis. Any joint can be affected by psoriatic arthritis, most commonly joints include:

Neck
Back
Shoulders
Elbows
Knees

For instance, according to a June 2020, report published in BioMed Central Ltd., an online patient-based global survey was conducted by The Harris Poll in Australia, Brazil, Canada, France, Spain, Taiwan, the U.K., and the U.S. between November 2, 2017 and March 12, 2018. Furthermore, according to survey the prevalence of psoriatic arthritis (PsA) has been reported as ranging from 0.01 to 1% depending on geographic region and it has been estimated that around 6–42% of patients with psoriasis develop PsA.

Global Psoriatic Arthritis Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. For instance, in a report published in March 2021, in The Journal of Rheumatology, the message from rheumatologists, dermatologists, infectious disease specialists, and patient research partners was that data did not suggest that having PsD or its treatment significantly increased risk of infection or more severe disease course, and that the telehealth experience was a success overall.

The global psoriatic arthritis market is estimated to be valued at US$ 8,953.9 Mn in 2021 and is expected to exhibit a CAGR of 11.40% over the forecast period (2021-2028).

Figure 1: Global Psoriatic Arthritis Market Share (%) Analysis, By Drug Class, 2021

Increasing number of drug approvals from regulatory bodies is a major factor driving the market growth over the forecast period.

Market players are focusing on gaining drug approvals from regulatory bodies, which is expected to drive the growth of global psoriatic arthritis market during the forecast period. For instance, in October 2018, Sandoz, a Novartis division, announced that the U.S. Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The US FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn’s disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).

Adoption of inorganic strategies by the market players is expected to drive the market growth during the forecast period.

Distribution agreements and partnerships by key players are expected to boost the market growth during the forecast period. For instance, in August 2019, Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver, and inflammatory diseases, announced that the company had signed a distribution agreement with Kyongbo Pharm Co., Ltd., a pharmaceutical and medicine manufacturing industry, to distribute Can-Fite’s lead drug candidate, Piclidenoson (CF101), for the treatment of psoriasis in South Korea.

Psoriatic Arthritis Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 8,953.3 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	11.40%	2028 Value Projection:	US$ 19,013.9 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease-modifying Antirheumatic Drugs (DMARDs), Biologics, Others By Product Type: Prescription, Over the counter. By Route of Administration: Topical, Oral, Injectable By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc., UCB S.A., and AstraZeneca plc.
Growth Drivers:	Increasing number of drug approvals from regulatory bodies Adoption of inorganic strategies by the market players such as signing various distribution agreements
Restraints & Challenges:	Availability of alternate treatments

Global Psoriatic Arthritis Market – Restraints

Availability of alternate treatment for psoriatic arthritis is expected to hinder the growth of the global psoriatic arthritis market during the forecast period.

For instance, according to The Center Orthopedic & Neurosurgical Care & Research, almost one million hip and knee replacement surgeries are performed in the U.S. annually, making it one of the most common orthopedic procedures performed. By 2030, total knee replacement surgeries are projected to grow 673% to 3.5 million procedures per year globally. Nearly 1/2 of the American adults are expected to develop knee osteoarthritis in at least one knee in their lifetime.

Global Psoriatic Arthritis Market – Regional Analysis

Increasing number of drugs approvals by regulatory bodies is expected to drive the growth of the North America psoriatic arthritis market during the forecast period.

For instance, in June 2021, AbbVie Inc., a research-based global biopharmaceutical company, announced that Health Canada has approved RINVOQ (upadacitinib, 15 mg), an oral, once-daily selective and reversible Janus kinase (JAK) inhibitor for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs)

Figure 2: Global Psoriatic Arthritis Market Value (US$ Mn), by Region, 2021

Global Psoriatic Arthritis Market – Competitive Landscape

Major players operating in the global psoriatic arthritis market include AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc., UCB S.A., and AstraZeneca plc.

Table of Content

*Browse 39 market data tables and 22 figures on "Psoriatic Arthritis Market” - Global Forecast to 2028.

N/A

- Frequently Asked Questions -

What will be the compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

The global psoriatic arthritis market is expected to exhibit a CAGR of 11.40% during the forecast period (2021-2028).

What is the estimated market size of the market in 2021?

The market is estimated to be valued at US$ 8,953.3 Mn in 2021.

Which are the prominent players operating in the market across the globe?

AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc., UCB S.A., and AstraZeneca plc., are some of the prominent players operating in the market over the forecast period.

What are the growth estimates for the market till 2028?

The market is expected to be valued at US$ 19,013.9 Mn in 2028.

Which is the mostly used drug class in the market?

Non-steroidal anti-inflammatory drugs (NSAIDs) is the mostly used drug class in the market.

Which is the prominent region in the market?

North America is the prominent region in the market.